

# Special Issue

## Clinical Trials of Sarcoma

### Message from the Guest Editor

This Special Issue focuses on advancements in clinical trials for sarcoma, a rare and diverse group of cancers arising in connective tissues. Despite significant challenges in treatment due to its heterogeneity, recent breakthroughs in targeted therapies, immunotherapy, and precision medicine are reshaping outcomes for sarcoma patients. This collection invites original research, reviews, and case studies highlighting innovative trial designs, biomarker-driven strategies, and translational approaches. By showcasing cutting-edge developments and collaborative efforts, this Special Issue aims at advancing understanding and fostering new therapeutic strategies to improve survival and quality of life for sarcoma patients worldwide.

---

### Guest Editor

Dr. Patrick Schlegel

University Hospital of Regensburg, Department of Pediatric Hematology, Oncology and Stem Cell Transplantation, 93053 Regensburg, Germany

---

### Deadline for manuscript submissions

closed (25 November 2025)



## Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/si/225573](https://mdpi.com/si/225573)

*Cancers*  
Editorial Office  
MDPI, Grosspeteranlage 5  
4052 Basel, Switzerland  
Tel: +41 61 683 77 34  
[cancers@mdpi.com](mailto:cancers@mdpi.com)

[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)





# Cancers

---

an Open Access Journal  
by MDPI

---

Impact Factor 4.4  
CiteScore 8.8  
Indexed in PubMed



[mdpi.com/journal/  
cancers](https://mdpi.com/journal/cancers)



## About the Journal

### Message from the Editor-in-Chief

*Cancers* (ISSN 2072-6694) is an international, online journal addressing both clinical and basic science issues related to cancer research. The journal will continue its open access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

---

### Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

---

### Author Benefits

#### Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

#### High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

#### Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)